Services

Histology

Pharmacology

Medical Device Testing

In Vitro Screening

Animal Model Development

Custom Assay Development

Vivarium Rental

Toxicology

Species

Non-human Primates

Dogs

Mini-Pigs / Pigs

Rabbits

Mice

Rats

Sheep

Guinea Pigs

Hamsters

Other Species

Therapeutic Areas

Oncology

Immunology & Inflammation

Neurology / CNS

Cardiovascular

Dermatology & Wound Healing

Metabolism

Gastroenterology

Hepatology

Pulmonology

Infectious Diseases & Sepsis

Musculoskeletal

Nephrology & Urology

Capabilities

GLP / IND-Enabling Studies

Small and Large Animal Housing

Bioanalytical Platforms

About

News

Contact

Career

Request a Quote

Logo
☰
  • Services ⌄
    • Histology
    • Pharmacology
    • Medical Device Testing
    • In Vitro Screening
    • Animal Model Development
    • Custom Assay Development
    • Vivarium Rental
    • Toxicology
  • Species ⌄
    • Non-human Primates
    • Dogs
    • Mini-Pigs / Pigs
    • Rabbits
    • Mice
    • Rats
    • Sheep
    • Guinea Pigs
    • Hamsters
    • Other Species
  • Therapeutic Areas ⌄
    • Oncology
    • Immunology & Inflammation
    • Neurology / CNS
    • Cardiovascular
    • Dermatology & Wound Healing
    • Metabolism
    • Gastroenterology
    • Hepatology
    • Pulmonology
    • Infectious Diseases & Sepsis
    • Musculoskeletal
    • Nephrology & Urology
  • Capabilities ⌄
    • GLP / IND-Enabling Studies
    • Small and Large Animal Housing
    • Bioanalytical Platforms
  • About ⌄
    • News
  • Contact ⌄
    • Career
    • Request a Quote

Expert Insights on Process Validation for Devicemakers

  • Post author:PacConAdmin
  • Post published:April 28, 2023
  • Post category:Drug Industry Daily

The FDA requires devicemakers to verify that a product meets each of its design specifications, which is generally accomplished through postproduction inspection or testing. Source: Drug Industry Daily

Continue ReadingExpert Insights on Process Validation for Devicemakers

Takeda Gets Thumbs-Up on Subcutaneous Entyvio BLA

  • Post author:PacConAdmin
  • Post published:April 28, 2023
  • Post category:Drug Industry Daily

Takeda has another shot on goal for a self-administered subcutaneous form of its blockbuster Entyvio (vedolizumab) as maintenance treatment for patients with ulcerative colitis who have completed induction therapy with…

Continue ReadingTakeda Gets Thumbs-Up on Subcutaneous Entyvio BLA

Illumina DNA Sequencing Devices Found Vulnerable to Hacking

  • Post author:PacConAdmin
  • Post published:April 28, 2023
  • Post category:Drug Industry Daily

The FDA has warned users of a vulnerability in Illumina’s genetic sequencing devices that could allow an authorized user to make changes to data from the devices. Source: Drug Industry…

Continue ReadingIllumina DNA Sequencing Devices Found Vulnerable to Hacking

Regulatory Update — Week of April 24, 2023

  • Post author:PacConAdmin
  • Post published:April 28, 2023
  • Post category:Drug Industry Daily

Over the past week, the FDA issued an authorization of a medical device, a request for comments for a public workshop and proposed data and information collections. Source: Drug Industry…

Continue ReadingRegulatory Update — Week of April 24, 2023

CHMP Endorses Adult RSV Vaccine, Six Other New Drugs in April Meeting

  • Post author:PacConAdmin
  • Post published:April 27, 2023
  • Post category:Drug Industry Daily

The European Medicines Agency’s (EMA) human medicines committee has signed off on GSK’s Arexvy (recombinant, adjuvanted), the first respiratory syncytial virus (RSV) vaccine for adults age 60 years and older…

Continue ReadingCHMP Endorses Adult RSV Vaccine, Six Other New Drugs in April Meeting

Akorn Pharmaceuticals Recalls Unexpired Drugs as It Completes Final Shutdown

  • Post author:PacConAdmin
  • Post published:April 27, 2023
  • Post category:Drug Industry Daily

Akorn Pharmaceuticals is recalling dozens of unexpired human and animal drug products in connection with a Chapter 7 bankruptcy filing, ending a five-year struggle to stay afloat through court battles…

Continue ReadingAkorn Pharmaceuticals Recalls Unexpired Drugs as It Completes Final Shutdown

EMA to Resume Trial Data Publication Efforts in September

  • Post author:PacConAdmin
  • Post published:April 27, 2023
  • Post category:Drug Industry Daily

Starting in September, the European Medicines Agency (EMA) will begin gradually resuming its efforts to openly share clinical trial data for medical products, the agency reported. Source: Drug Industry Daily

Continue ReadingEMA to Resume Trial Data Publication Efforts in September

Pharmaplast Receives Warning Letter for Product Testing, Equipment Cleaning Issues

  • Post author:PacConAdmin
  • Post published:April 27, 2023
  • Post category:Drug Industry Daily

Egypt’s Pharmaplast received an FDA warning letter on April 13 for failing to address drug component testing and equipment maintenance issues. Source: Drug Industry Daily

Continue ReadingPharmaplast Receives Warning Letter for Product Testing, Equipment Cleaning Issues

Voyant Beauty Handed Warning Letter for Contamination Issues

  • Post author:PacConAdmin
  • Post published:April 27, 2023
  • Post category:Drug Industry Daily

Elkhart-Ind.-based Voyant Beauty, a division of Accra-Pac, received an FDA warning letter on April 20 for not appropriately addressing benzene contamination of its over-the-counter topical aerosol products, found during an…

Continue ReadingVoyant Beauty Handed Warning Letter for Contamination Issues

Medivance Handed FDA Warning Letter for Modifying Device After Clearance

  • Post author:PacConAdmin
  • Post published:April 27, 2023
  • Post category:Drug Industry Daily

Significantly modifying its Velopex Aquacut fluid abrasion unit in multiple ways without submitting a new 510(k) clearance application has resulted in the UK’s Medivance Instruments receiving a Feb. 13 warning…

Continue ReadingMedivance Handed FDA Warning Letter for Modifying Device After Clearance
  • Go to the previous page
  • 1
  • …
  • 25
  • 26
  • 27
  • 28
  • 29
  • 30
  • 31
  • …
  • 385
  • Go to the next page

Stay Connected

Keep up with the latest news & insights.

Contact Us

Phone:
+1 858-605-5882
Fax:
+1 858-605-5916
Email:
info@biolegacyresearch.com
Mail:

6042 Cornerstone Court W

Suite E

San Diego, CA 92121

Social:
© 2025 BioLegacy Research. All rights reserved.